eurogenic stuttering: Characteristics and treatment

Not Applicable

• Conditions: eurogenic stuttering; Parkinson's disease; Traumatic Brain Injury; Stroke; Neurogenic stuttering; Neurological - Parkinson's disease; Injuries and Accidents - Other injuries and accidents; Stroke - Haemorrhagic; Stroke - Ischaemic

• Registration Number: ACTRN12621001129875
• Lead Sponsor: niversity of Canterbury

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2021-08-23
• Last Update Posted: 30 August 2021

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

Diagnosis of neurological condition (e.g. Parkinson’s disease or Traumatic Brain Injury) and presenting with stuttering dysfluencies.
Ability to provide informed consent.
Ability to participate in assessment sessions, treatment sessions (if participant opts to undergo treatment), and undergo MRI scanning (if participant opts to participate in study arm 3).

Exclusion Criteria

Receiving other therapy for stuttering precludes from participation in arm 2 of the study.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Changes to frequency of dysfluencies as measured by Stuttering Severity Index - Edition 4.[During 20th hour of therapy.];Changes to the impact of dysfluencies on communicative participation as measured by the Communicative Participation Item Bank.[During 20th hour of therapy.];Changes to quality of life as measured by the Overall Assessment of the Speaker's Experience of Stuttering.[During 20th hour of therapy.]

Secondary Outcome Measures

Name	Time	Method
europlastic changes associated with therapy for neurogenic stuttering completed during part 2 identified through fMRI.[Within seven days of concluding 20 hours of therapy.]